Penn Medicine
Help | Search | Site Map | Contact   
faculty photo

Thomas P. Cappola, MD, ScM

Herbert C. Rorer Associate Professor in Medical Sciences
Department: Medicine
Graduate Group Affiliations

Contact information
Division of Cardiovascular Medicine
9035 West Gates
3400 Spruce Street
Philadelphia, PA 19104
Office: 215-662-3140
Fax: 215-349-8017
Lab: 215-573-4717
Education:
A.B. (Chemistry)
Princeton University, 1991.
M.D. (Medicine)
Harvard Medical School, 1995.
Sc.M. (Clinical Investigation )
Johns Hopkins Bloomberg School of Public Health, 2004.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of CVI Expertise

CVI Program Unit(s):
Myocyte Biology / Heart Failure
Biotechnology / Nanomedicine / Imaging

CVI Research Description:
My group studies mechanisms of human heart failure using genomics, biomarkers, and proof-of-concept studies of novel therapeutics.

Current projects include:

1) The Penn Heart Failure Study (PHFS):
An NHLBI funded prospective observational cohort study of subjects with wide range of heart failure whose broad aim is to detect genomic and proteomic modifiers of heart failure progression. Recruitment (n = 2,300) is complete and a variety of analyses are underway.

2) Myocardial Applied Genomics Network (MAGNet)
This NHLBI funded program leverages the world's largest human myocardial biobank to for human myocardial eQTL mapping and systems genetics.

3) NHLBI Heart Failure Clinical Research Network
A phase two clinical trials network to test novel treatment strategies for advanced heart failure. We are currently leading a multi-center trial of liraglutide in patients with heart failrue and reduced ejection fraction.

Selected Publications

Margulies KB, Hernandez A, Redfield M, Givertz M, Oliveira G, Cole R, Mann D, Whellan D, Kiernan M, Felker GM, McNulty S, Anstrom K, Shah S, Eugene Braunwald E, Cappola TP: Effects of liraglutide on clinical stability in advanced heart failure with reduced ejection fraction: a randomized clinical trial. JAMA 316(5): 500-508, Aug 2016.

AbouEzzeddine OF, French B, Mirzoyev SA, Jaffe AS, Levy WC, Fang JC, Sweitzer NK, Cappola TP, Redfield MM: From statistical significance to clinical relevance: A simple algorithm to integrate brain natriuretic peptide and the Seattle Heart Failure Model for risk stratification in heart failure. J Heart Lung Transplant 35(6): 714-21, Jun 2016 Notes: Epub 2016 Jan 15.

Smith JG, Felix J, Morrison AC, Kalogeropoulos A, Trompet S, Wilk JB, Gidlöf O, Wang X, Morley M, Mendelson M, Joehanes R, Ligthart S, Shan X, Bis JC, Wang YA, Sjögren M, Ngwa J, Brandimarto J, Stott D, Aguilar D, Rice KM, Sesso HD, Demissie S, Buckley BM, Taylor KD, Ford I, Yao C, Liu C, Sotoodehnia N, van der Harst P, Stricker BHC, Kritchevsky SB, Liu Y, Gaziano JM, Hofman A, Moravec CS, Uitterlinden AG, Kellis M, van Meurs JB, Margulies KB, Dehghan A, Levy D, Olde B, Psaty BM, Cupples LA, Jukema J, Djousse L, Franco OH, Boerwinkle E, Boyer LA, Newton-Cheh C, Butler J, Vasan R, Cappola TP, Smith NL: Discovery of genetic variation on chromosome 5q22 associated with mortality in heart failure. PLoS Genet 12(5): e1006034, May 2016.

French B, Wang L, Ky B, Brandimarto J, Basuray A, Fang JC, Sweitzer NK, Cappola TP: Prognostic value of galectin-3 for adverse outcomes in chronic heart failure. J Card Fail 22(4): 256-62, Apr 2016.

de Denus S, Rouleau JL, Mann DL, Huggins GL, Cappola TP, Shah S, Keleti J, Zada YF, Provost S, Bardhadi A, Phillips MS, Normand V, Mongrain I, Dube MP: A pharmacogenetic investigation of intravenous furosemide in decompensated heart failure: a meta-analysis of 3 clinical trials Pharmacogenomics J March 1 2016 Notes: Epub ahead of print.

French B, Saha-Chaudhuri P, Ky B, Cappola TP, Heagerty PJ: Development and evaluation of multi-marker risk scores for clinical prognosis. Stat Methods Med Res 25(1): 255-271, Feb 2016.

Keenan T, Zhao W, Rasheed A, Ho WK, Malik R, Felix JF, Young R, Shah N, Samuel M, Sheikh N, Mucksavage ML, Shah O, Li J, Morley M, Laser A, Mallick NH, Zaman KS, Ishaq M, Rasheed SZ, Memon FU, Ahmed F, Hanif B, Lakhani MS, Fahim M, Ishaq M, Shardha NK, Ahmed N, Mahmood K, Iqbal W, Akhtar S, Raheel R, O'Donnell CJ, Hengstenberg C, März W, Kathiresan S, Samani N, Goel A, Hopewell JC, Chambers J, Cheng YC, Sharma P, Yang Q, Rosand J, Boncoraglio GB, Kazmi SU, Hakonarson H, Köttgen A, Kalogeropoulos A, Frossard P, Kamal A, Dichgans M, Cappola T, Reilly MP, Danesh J, Rader DJ, Voight BF, Saleheen D: Causal assessment of serum rrate levels in cardiometabolic diseases through a Mendelian randomization study. J Am Coll Cardiol 2(67): 407-16, Feb 2016.

Ware JS, Li J, Mazaika E, Yasso CM, DeSouza T, Cappola TP, Tsai EJ, Hilfiker-Kleiner D, Kamiya CA, Mazzarotto F, Cook SA, Halder I, Prasad SK, Pisarcik J, Hanley-Yanez K, Alharethi R, Damp J, Hsich E, Elkayam U, Sheppard R, Kealey A, Alexis J, Ramani G, Safirstein J, Boehmer J, Pauly DF, Wittstein IS, Thohan V, Zucker MJ, Liu P, Gorcsan J 3rd, McNamara DM, Seidman CE, Seidman JG, Arany Z: Shared genetic predisposition in peripartum and dilated cardiomyopathies. N Engl J Med 374(3): 233-41, Jan 2016.

Perez MV, Pavlovic A, Shang C, Wheeler MT, Miller CL, Liu J, Dewey FE, Pan S, Thanaporn PK, Absher D, Brandimarto J, Salisbury H, Chan K, Mukherjee R, Konadhode RP, Myers RM, Sedehi D, Scammell TE, Quertermous T, Cappola T, Ashley EA: Systems genomics identifies a key role for hypocretin/orexin receptor-2 in human heart failure. J Am Coll Cardiol 66(22): 2522-33, Dec 2015.

Das A, Morley M, Moravec CS, Tang WH, Hakonarson H; MAGNet Consortium, Margulies KB, Cappola TP, Jensen S, Hannenhalli S: Bayesian integration of genetics and epigenetics detects causal regulatory SNPs underlying expression variability. Nat Commun 6: 8555, Oct 2015.

back to top
Last updated: 09/19/2016
The Trustees of the University of Pennsylvania
 
© The Trustees of the University of Pennsylvania. Site best viewed with Mozilla, NN, IE, or Safari.
SOM Home International Programs Penn Alumni Clinical Trials Centers and Institutes Departments Faculty Research Education Administration